paul
Researcher
Posts: 134
|
Post by paul on Oct 3, 2019 20:07:13 GMT -5
I just listened to the call. I heard nothing new. Did anyone else? Some new tidbits and/or insights for me were... - MC's reference to the TS platform as the companies "secret sauce", it's the foundation and will be very important (maybe more important than Afrezza?) in the company's future. It seemed to me in the past that the company had been performing this very delicate balancing act of "where does our money go?". My takeaway is that more focused investing into the TS platform compound development now is needed for future support of Afrezza growth. I've wondered where the priority was in the past, but this provided some clarity of me. Not saying it's right or wrong, some folks have strong opinions on that, but that was just some clarity from my perspective.
- Brazil shipment is at or through customs.
- MC referred to the pediatric study more in this presentation that any other from memory. He linked it to changing the standard of care and put a 20-year time from on it. I don't think he actually meant the ADA SOC, but diabetic behavior in general once the pioneer pediatric users of Afrezza continue use in the future as adults. With P3 peds trial to start in 2020, through FDA approval and trial participants reaching adulthood...about 20 years. Can't say that number excited me much, but ultimately getting the peds approval would be huge...still a couple years out though.
- No decision has been made regarding the undisclosed UTHR molecule...despite rumors to the contrary. The molecule is scheduled to start rodent toxicity studies in Q4 or Q1-2020.
- When talking about the pipeline, MC referred to a 2-5 year time frame for receiving milestones payments from UTHR and RLS. Work continues for RLS for an FDA approved product (probably some non FDA as well?). This is the first time I can remember an actual number put on RLS milestones. It's not exactly nailed down by any means, but I think the "2" refers to UTHR and the "5" likely refers to RLS. I hope the 5 is on the conservative side.
- The Pfizer safety data for Exhubra was brought up and referred to as safety data for "inhaled insulin". We already knew it was out there but I think it was the first time presented at an investor conference. (Why did Pfizer do that?...seems odd).
- While at the conference MC met with a group of physicians and asked who was stuck on Afrezza dosing limitations with 4, 8, 12. Apparently many were and MC said "Speed trumps accuracy". Afrezza's speed of action is more important than getting the RAA injected dose down to the fraction of a unit. That was portrayed as an "Ahha" moment to them. Maybe it was, maybe it wasn't, but I like the statement "Speed trumps accuracy" and hope it is used more often and sticks. I'm no doctor and there are probably some folks who don't agree with that statement, but I think it's catchy and straight to the point.
- Interest expense has been reduced from 20 mil to 4 mill on an annual basis. Assume it will now be paid for a longer time period, but at this point in time, that move makes sense.
- Towards the end of the presentation (Slide 24) collaborative revenue...MC says "I continue to get inbound calls for the platform to put other peoples drugs on our platform".
- One question during Q&A - Regarding Technosphere - "What's lead to the inbound interest in partnering given that TS has been around for awhile?" MNKD is going to start attending conferences specifically for inhaled platforms. MC referred to one in Europe where TS had been brought up as one to watch which generated three calls. MC also referred to the increased financial stability of the company as a reason for increased interest. It was interesting that whoever brought up TS at the Europe conference had no connection to MNKD and MC didn't know who they were.
One person's perspective... Are you sure he said interest went from 20 to 4 million? According to the last 10-Q -- www.globenewswire.com/news-release/2019/08/07/1898640/0/en/MannKind-Corporation-Reports-2019-Second-Quarter-Financial-Results-and-Recent-Business-Highlights.html -- presuming I'm reading it correctly, interest expense was 1.6 million or roughly 6 million a year. The new Mann group debt alone will be 7% of 70 million or about 5 million. And if Mannkind takes the entire 75 million of Midcap money, that's another 6 million or so. |
|
|
|
Post by wsb36 on Oct 3, 2019 20:49:41 GMT -5
Is there anywhere I could listen to the presentation?
|
|
|
|
Post by sportsrancho on Oct 3, 2019 20:55:19 GMT -5
|
|
|
|
Post by MnkdWASmyRtrmntPlan on Oct 3, 2019 20:57:53 GMT -5
Some new tidbits and/or insights for me were... - MC's reference to the TS platform as the companies "secret sauce", it's the foundation and will be very important (maybe more important than Afrezza?) in the company's future. It seemed to me in the past that the company had been performing this very delicate balancing act of "where does our money go?". My takeaway is that more focused investing into the TS platform compound development now is needed for future support of Afrezza growth. I've wondered where the priority was in the past, but this provided some clarity of me. Not saying it's right or wrong, some folks have strong opinions on that, but that was just some clarity from my perspective.
- Brazil shipment is at or through customs.
- MC referred to the pediatric study more in this presentation that any other from memory. He linked it to changing the standard of care and put a 20-year time from on it. I don't think he actually meant the ADA SOC, but diabetic behavior in general once the pioneer pediatric users of Afrezza continue use in the future as adults. With P3 peds trial to start in 2020, through FDA approval and trial participants reaching adulthood...about 20 years. Can't say that number excited me much, but ultimately getting the peds approval would be huge...still a couple years out though.
- No decision has been made regarding the undisclosed UTHR molecule...despite rumors to the contrary. The molecule is scheduled to start rodent toxicity studies in Q4 or Q1-2020.
- When talking about the pipeline, MC referred to a 2-5 year time frame for receiving milestones payments from UTHR and RLS. Work continues for RLS for an FDA approved product (probably some non FDA as well?). This is the first time I can remember an actual number put on RLS milestones. It's not exactly nailed down by any means, but I think the "2" refers to UTHR and the "5" likely refers to RLS. I hope the 5 is on the conservative side.
- The Pfizer safety data for Exhubra was brought up and referred to as safety data for "inhaled insulin". We already knew it was out there but I think it was the first time presented at an investor conference. (Why did Pfizer do that?...seems odd).
- While at the conference MC met with a group of physicians and asked who was stuck on Afrezza dosing limitations with 4, 8, 12. Apparently many were and MC said "Speed trumps accuracy". Afrezza's speed of action is more important than getting the RAA injected dose down to the fraction of a unit. That was portrayed as an "Ahha" moment to them. Maybe it was, maybe it wasn't, but I like the statement "Speed trumps accuracy" and hope it is used more often and sticks. I'm no doctor and there are probably some folks who don't agree with that statement, but I think it's catchy and straight to the point.
- Interest expense has been reduced from 20 mil to 4 mill on an annual basis. Assume it will now be paid for a longer time period, but at this point in time, that move makes sense.
- Towards the end of the presentation (Slide 24) collaborative revenue...MC says "I continue to get inbound calls for the platform to put other peoples drugs on our platform".
- One question during Q&A - Regarding Technosphere - "What's lead to the inbound interest in partnering given that TS has been around for awhile?" MNKD is going to start attending conferences specifically for inhaled platforms. MC referred to one in Europe where TS had been brought up as one to watch which generated three calls. MC also referred to the increased financial stability of the company as a reason for increased interest. It was interesting that whoever brought up TS at the Europe conference had no connection to MNKD and MC didn't know who they were.
One person's perspective... Are you sure he said interest went from 20 to 4 million? According to the last 10-Q -- www.globenewswire.com/news-release/2019/08/07/1898640/0/en/MannKind-Corporation-Reports-2019-Second-Quarter-Financial-Results-and-Recent-Business-Highlights.html -- presuming I'm reading it correctly, interest expense was 1.6 million or roughly 6 million a year. The new Mann group debt alone will be 7% of 70 million or about 5 million. And if Mannkind takes the entire 75 million of Midcap money, that's another 6 million or so. I didn't hear the presentation, but Mike was probably being deceitful again and referring to 20 million at some point in the past ... like, as high as 20 million. |
|
|
|
Post by goyocafe on Oct 3, 2019 20:59:04 GMT -5
First time in my investment tenure of this company that I either didn’t go out of my way to listen to the live presentation or the replay. Times have definitely changed. |
|
|
|
Post by brotherm1 on Oct 3, 2019 21:02:45 GMT -5
ditto
|
|
|
|
Post by wsulylecoug on Oct 3, 2019 21:05:51 GMT -5
Some new tidbits and/or insights for me were... - MC's reference to the TS platform as the companies "secret sauce", it's the foundation and will be very important (maybe more important than Afrezza?) in the company's future. It seemed to me in the past that the company had been performing this very delicate balancing act of "where does our money go?". My takeaway is that more focused investing into the TS platform compound development now is needed for future support of Afrezza growth. I've wondered where the priority was in the past, but this provided some clarity of me. Not saying it's right or wrong, some folks have strong opinions on that, but that was just some clarity from my perspective.
- Brazil shipment is at or through customs.
- MC referred to the pediatric study more in this presentation that any other from memory. He linked it to changing the standard of care and put a 20-year time from on it. I don't think he actually meant the ADA SOC, but diabetic behavior in general once the pioneer pediatric users of Afrezza continue use in the future as adults. With P3 peds trial to start in 2020, through FDA approval and trial participants reaching adulthood...about 20 years. Can't say that number excited me much, but ultimately getting the peds approval would be huge...still a couple years out though.
- No decision has been made regarding the undisclosed UTHR molecule...despite rumors to the contrary. The molecule is scheduled to start rodent toxicity studies in Q4 or Q1-2020.
- When talking about the pipeline, MC referred to a 2-5 year time frame for receiving milestones payments from UTHR and RLS. Work continues for RLS for an FDA approved product (probably some non FDA as well?). This is the first time I can remember an actual number put on RLS milestones. It's not exactly nailed down by any means, but I think the "2" refers to UTHR and the "5" likely refers to RLS. I hope the 5 is on the conservative side.
- The Pfizer safety data for Exhubra was brought up and referred to as safety data for "inhaled insulin". We already knew it was out there but I think it was the first time presented at an investor conference. (Why did Pfizer do that?...seems odd).
- While at the conference MC met with a group of physicians and asked who was stuck on Afrezza dosing limitations with 4, 8, 12. Apparently many were and MC said "Speed trumps accuracy". Afrezza's speed of action is more important than getting the RAA injected dose down to the fraction of a unit. That was portrayed as an "Ahha" moment to them. Maybe it was, maybe it wasn't, but I like the statement "Speed trumps accuracy" and hope it is used more often and sticks. I'm no doctor and there are probably some folks who don't agree with that statement, but I think it's catchy and straight to the point.
- Interest expense has been reduced from 20 mil to 4 mill on an annual basis. Assume it will now be paid for a longer time period, but at this point in time, that move makes sense.
- Towards the end of the presentation (Slide 24) collaborative revenue...MC says "I continue to get inbound calls for the platform to put other peoples drugs on our platform".
- One question during Q&A - Regarding Technosphere - "What's lead to the inbound interest in partnering given that TS has been around for awhile?" MNKD is going to start attending conferences specifically for inhaled platforms. MC referred to one in Europe where TS had been brought up as one to watch which generated three calls. MC also referred to the increased financial stability of the company as a reason for increased interest. It was interesting that whoever brought up TS at the Europe conference had no connection to MNKD and MC didn't know who they were.
One person's perspective... Are you sure he said interest went from 20 to 4 million? According to the last 10-Q -- www.globenewswire.com/news-release/2019/08/07/1898640/0/en/MannKind-Corporation-Reports-2019-Second-Quarter-Financial-Results-and-Recent-Business-Highlights.html -- presuming I'm reading it correctly, interest expense was 1.6 million or roughly 6 million a year. The new Mann group debt alone will be 7% of 70 million or about 5 million. And if Mannkind takes the entire 75 million of Midcap money, that's another 6 million or so. 6:15 of presentation |
|
|
|
Post by cretin11 on Oct 4, 2019 4:50:20 GMT -5
Just heard MC say he thinks scripts will be good tomorrow.Good way to open his presentation. Good scripts would be in the 2500-3000 range. He has set the bar very low for himself, because he doesn’t have a clue how to improve scripts Scripts aren’t where they should be, but I think we can all agree the numbers adri just posted in the script thread are in the right direction (for the first time in a few weeks). Sounds like Mike may have had a heads up on that. Maybe VDEX getting some traction? |
|
|
|
Post by sportsrancho on Oct 4, 2019 7:04:45 GMT -5
He did and yes they are:-)
|
|
|
|
Post by Clement on Oct 4, 2019 8:07:35 GMT -5
Or it could be Kaiser? But these weekly reports go in bumps and dips anyway even without Vdex or Kaiser. Today was indeed an impressive bump and makes me want an explanation.
|
|
|
|
Post by sugarland on Oct 4, 2019 8:39:11 GMT -5
Or it could be Kaiser? But these weekly reports go in bumps and dips anyway even without Vdex or Kaiser. Today was indeed an impressive bump and makes me want an explanation. I’m my opinion, Just a result of “law of average” and “element of time”, from past 3-4 months of sitting around 600. I don’t expect any justification for this weeks bump up. It was long over due to roll one way or another. It’s just nice to see it bump the right direction. If this sets a new approximate floor heading into Q4, it will bring warrants into play, and some long overdue joy for share holders finally. Still need 2,000 a week minimum before the real fun starts. |
|
|
|
Post by mytakeonit on Oct 4, 2019 13:25:09 GMT -5
Where do we add in the container shipment to Brazil? I'm waiting for that to top it off.
But, that's mytakeonit
|
|
